fullscreen

eFinder

eFinder

Home › Article

Weight-loss drugs linked to lower breast cancer risk, study finds

EuroNews · 🇫🇷 public France · · 514 words · By Marta Iraola Iribarren
headphones Listen to the eFinder podcast briefing
Ready to play
Daily briefing

What to know about Weight-loss drugs linked to lower breast cancer risk, study finds

Women on weight-loss medication may have a lower risk of developing breast cancer, according to a new study.

Claims checked 8
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center75%
Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Women on weight-loss medication may have a lower risk of developing breast cancer, according to a new study.

Why it matters

Women who take GLP-1 medications, such as Ozempic or Mounjaro, are less likely to develop breast cancer, a new study has found.

Common ground

The findings, presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, come from an analysis of more than 110,000 women aged between 45 and 80.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.euronews.com/health/2026/06/04/weight-loss-drugs-may-cut-breast-canc…

fact_checkClaims Checked

eFinder analyzed this article and checked 8 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 4
info Single Source 3
verified Verified 1
check_circle
Claim 1: “These medications promote weight loss and improve markers of metabolic health.”
CORROBORATED
Multiple sources (SheMed UK, Altum Health, and a general GLP-1 benefits search result) confirm that GLP-1 medications promote weight loss and improve metabolic health markers.
travel_explore
web search NEUTRAL — Weight Loss and Metabolic Health.By promoting weight loss through lifestyle changes or medications like GLP-1 agonists, women may find relief from both hot flushes and mood-related symptoms, leading t…
https://www.shemed.co.uk/blog/weight-loss/perimenopause-and-…
travel_explore
web search NEUTRAL — For people with obesity-related health conditions, GLP-1 medications can offer significant benefits. They can support weight loss and improve cardiovascular and metabolic health markers when prescribe…
https://www.altumhealth.co.uk/ozempic-eating-disorders/
travel_explore
web search NEUTRAL — Discover how GLP-1 receptor agonists like semaglutide and tirzepatide enhance blood sugar control, boost insulin sensitivity, and protect cardiovascular health while aiding in weight loss.
https://www.tuyohealth.com/blogs/glp1-medications-weightloss
info
Claim 2: “A separate Italian study found that women with advanced, hormone receptor-positive breast cancer — the most common type of breast cancer — who took GLP-1 drugs lived on average nearly 19 months longer than those who did not.”
SINGLE SOURCE
The specific finding regarding an Italian study and the 19-month survival increase for hormone receptor-positive breast cancer is reported in one web search result, but not corroborated by other independent sources in the provided set.
menu_book
wikipedia NEUTRAL — The Principles of Good Laboratory Practice (GLP) establish rules and criteria for a quality system that oversees the organizational processes and conditions in which non-clinical (non-pharmaceutical) …
https://en.wikipedia.org/wiki/Good_laboratory_practice
menu_book
wikipedia NEUTRAL — The Green Liberal Party of Switzerland (German: Grünliberale Partei der Schweiz, GLP; Romansh: Partida verda-liberala, PVL; French: Parti vert'libéral, PVL; Italian: Partito verde liberale, PVL), is a…
https://en.wikipedia.org/wiki/Green_Liberal_Party_of_Switzer…
menu_book
wikipedia NEUTRAL — Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first…
https://en.wikipedia.org/wiki/Liraglutide
+ 3 more evidence sources
check_circle
Claim 3: “They work by mimicking natural hormones produced in the gut after eating, signaling the body to release more insulin, reduce appetite and keep blood sugar levels low.”
CORROBORATED
Multiple sources (Valuemed, AORN, and SheMed UK) explain the mechanism of GLP-1s: mimicking gut hormones, increasing insulin release, reducing appetite, and lowering blood sugar.
travel_explore
web search NEUTRAL — Mechanism: Increase insulin release when glucose rises, reduce glucagon secretion, and improve blood sugar control. Impact: Lower fasting glucose, lower HbA1c, and reduced glycaemic variability. 2. Ob…
https://www.valuemed.co.uk/blogs/news/what-are-glp-1-medicat…
travel_explore
web search NEUTRAL — They increase insulin release when glucose is high and decrease glucagon to help control blood sugar. Be familiar with common patient populations using GLP-1 therapy Patients prescribed GLP-1 medicati…
https://www.aorn.org/article/5-things-every-or-nurse-should-…
travel_explore
web search NEUTRAL — These medications can promote feelings of fullness, reduce appetite, and support healthier eating habits, facilitating weight management. Maintaining a healthy weight can alleviate some stressors link…
https://www.shemed.co.uk/blog/weight-loss/perimenopause-and-…
verified
Claim 4: “Breast cancer is one of the most common malignant tumors in women worldwide”
VERIFIED
The World Health Organization (WHO) and PMC both explicitly state that breast cancer is the most common cancer/malignant tumor in women globally.
travel_explore
web search NEUTRAL — 3 days ago ... Key facts · Breast cancer caused an estimated 694 000 deaths globally in 2024 and was the most common cancer in women in 164 countries out of 186 ...
https://www.who.int/news-room/fact-sheets/detail/breast-canc…
travel_explore
web search NEUTRAL — Breast cancer is the most common cancer among women. It is estimated that 2.3 million new cases of BC are diagnosed globally each year.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8428369/
travel_explore
web search NEUTRAL — Mar 18, 2025 ... Breast cancer is the most prevalent malignant disease among women and affects women of reproductive age (15–49 years) across the globe. This ...
https://www.nature.com/articles/s41598-025-93883-9
info
Claim 5: “The study found that women who had used GLP-1 medications were around 30% less likely to develop breast cancer, independent of age, race, ethnicity, BMI, breast density and diabetes.”
SINGLE SOURCE
The specific 30% figure and the list of independent variables (age, race, BMI, etc.) are mentioned in the Penn Medicine search result, but not independently corroborated by a second distinct news organization in the provided evidence.
menu_book
wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-1RAs, and informally as simply GLP-1s, are a class of medications that activate the GLP-1 receptor, causing reduced…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist
menu_book
wikipedia NEUTRAL — Being overweight is having more body fat than is considered healthy. The World Health Organization (WHO) classifies people as overweight when their body mass index (BMI)—a person's weight divided by t…
https://en.wikipedia.org/wiki/Overweight
menu_book
wikipedia NEUTRAL — Polyendocrine metabolic ovarian syndrome (PMOS), previously called polycystic ovary syndrome (PCOS), is the most common hormonal disorder in women of reproductive age. PMOS is diagnosed when a woman h…
https://en.wikipedia.org/wiki/Polyendocrine_metabolic_ovaria…
+ 3 more evidence sources
info
Claim 6: “The study was restricted to women with overweight and obesity”
SINGLE SOURCE
While the evidence contains general information about overweight and obesity, none of the provided search results specifically confirm that the breast cancer study mentioned in Claim 0 was restricted only to women with overweight and obesity.
travel_explore
web search NEUTRAL — Jun 5, 2018 ... Majority of respondents in this study were overweight and obese (54.3%) compared with 45.7% being non-obese. A linear positive association of ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC5989365/
travel_explore
web search NEUTRAL — Jul 14, 2025 ... More men (21.9%) than women (15.6%) were newly classified as PWO; the newly classified PWO were older (51.3 years; standard deviation [SD], 14.5) ...
https://www.2minutemedicine.com/new-obesity-framework-may-re…
travel_explore
web search NEUTRAL — Oct 10, 2011 ... Adjusted multinomial logistic regression analyses showed lesbians have more than twice the odds of overweight (odds ratio [OR]=2.69; 95% ...
https://ajph.aphapublications.org/doi/10.2105/AJPH.2006.0884…
check_circle
Claim 7: “Women who take GLP-1 medications, such as Ozempic or Mounjaro, are less likely to develop breast cancer, a new study has found.”
CORROBORATED
Multiple independent web search results (Penn Medicine and another source) report that GLP-1 medications are linked to a lower incidence of breast cancer, specifically mentioning a 30% reduction.
travel_explore
web search NEUTRAL — Jun 2, 2026 ... A retrospective analysis of more than 110000 women found that those who took GLP-1 medications were about 30 percent less likely to develop ...
https://www.pennmedicine.org/news/glp-1-use-linked-to-lower-…
travel_explore
web search NEUTRAL — Dec 29, 2025 ... While research into GLP-1 medications and breast cancer is in its early stages, there are indications that these drugs could be an important ...
https://www.bcrf.org/blog/what-you-need-to-know-about-glp-1s…
travel_explore
web search NEUTRAL — Jun 4, 2026 ... Taken together, they suggest that people taking medications such as Ozempic, Wegovy and Mounjaro may develop certain cancers at lower rates than ...
https://www.washingtonpost.com/health/2026/06/03/science-aro…
check_circle
Claim 8: “The findings, presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, come from an analysis of more than 110,000 women aged between 45 and 80.”
CORROBORATED
Web search results explicitly mention the 2026 ASCO Annual Meeting and research presented there. The specific detail about 110,000 women is corroborated by the Penn Medicine search result.
menu_book
wikipedia NEUTRAL — Abelardo Gabriel de la Espriella Otero (Latin American Spanish: [aβeˈlaɾðo ɣaˈβɾjel ðe la esˈpɾjeʝa oˈteɾo]; born 31 July 1978) is a Colombian lawyer, businessman, and far-right politician who is the …
https://en.wikipedia.org/wiki/Abelardo_de_la_Espriella
menu_book
wikipedia NEUTRAL — The MOBO Awards 2026 was the 28th edition of the MOBO Awards. It took place on 26 March 2026, at the Co-op Live in Manchester, England. It honoured achievements in music of black origin. Live streamed…
https://en.wikipedia.org/wiki/MOBO_Awards_2026
menu_book
wikipedia NEUTRAL — Rusfertide is an investigational new drug that is being developed by Protagonist Therapeutics in partnership with Takeda for the treatment of polycythemia vera (PV).
https://en.wikipedia.org/wiki/Rusfertide
+ 3 more evidence sources
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.